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Abstract: The Alpha One International Registry (AIR), a multinational research program 
focused on alpha1-antitrypsin (AAT) deﬁ  ciency, was formed in response to a World Health 
Organization recommendation. Each of the nearly 20 participating countries maintains a national 
registry of patients with AAT deﬁ  ciency and contributes to an international database located 
in Malmö, Sweden. This database is designed to increase understanding of AAT deﬁ  ciency. 
Additionally, AIR members are engaged in active, wide-ranging investigations to improve the 
diagnosis, monitoring, and treatment of the disease and meet biennially to exchange views 
and research ﬁ  ndings. The fourth biennial meeting was held in Copenhagen, Denmark, on 
2–3 June 2005. This review covers the wide range of AAT deﬁ  ciency-related topics that were 
addressed encompassing advances in genetic characterization, risk factor identiﬁ  cation, clinical 
epidemiology, inﬂ  ammatory and signalling processes, therapeutic advances, and lung imaging 
techniques.
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Introduction
Alpha1-antitrypsin (AAT) deﬁ  ciency was ﬁ  rst reported in 1963 by Carl-Bertil Laurell 
and Sten Eriksson (Laurell and Eriksson 1963) who noted a link between low 
plasma serum levels of AAT and symptoms of pulmonary emphysema. Since these 
ﬁ  rst cases were described, an understanding of the biochemical mechanisms and 
genetic abnormalities involved has developed, and AAT deﬁ  ciency is now thought 
to be one of the most common hereditary disorders worldwide, comparable in 
frequency to cystic ﬁ  brosis (WHO 1997; de Serres 2002). The most frequent clinical 
complications of AAT deﬁ  ciency are pulmonary emphysema of the panacinar type, 
which may present as early as the third or fourth decade, and liver disease, which 
typically presents early in infancy as neonatal hepatitis with a diverse degree of liver 
involvement and outcome (ATSERS 2003). The development of AAT augmentation 
therapy in 1987 provided an option for physicians seeking to improve the course of 
this disease (Wewers et al 1987), and research into other potential treatments such 
as gene therapy is ongoing.
The Alpha One International Registry (AIR), formed in 1998, is a multinational 
research project involving nearly 20 countries. AIR was started to fulﬁ  ll the World 
Health Organization (WHO) recommendation for the establishment of an international 
registry for AAT deficiency (WHO 1997). Including subjects identified by a 
standardized mechanism to create a common database, AIR can be considered central 
to resolving many of the unanswered questions in AAT deﬁ  ciency. AIR is committed 
to organizing scientiﬁ  c meetings every 2 years to update the medical and scientiﬁ  c 
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community on the progress of research in AAT deﬁ  ciency. 
The ﬁ  rst meeting was held in 1999 in Cernobbio-Como, 
Italy (Stockley 1999), and subsequent meetings have 
been held in Genoa, Italy, in 2001(Luisetti et al 2002) and 
Barcelona, Spain, in 2003 (Navickis and Wilkes 2004). The 
fourth AIR meeting was held in Copenhagen, Denmark, on 
2–3 June 2005 and involved 26 speakers in a concentrated 
2-day scientiﬁ  c program. The highlights of this meeting are 
reported in this review.
The Laurell Lecture
In recognition of Carl-Bertil Laurell’s work on AAT 
deficiency, the AIR Laurell Lecture was established in 
2003 to acknowledge those who have made a substantial 
contribution to the knowledge base in AAT deﬁ  ciency. Robin 
W Carrell was the ﬁ  rst to present such a lecture (Navickis 
and Wilkes 2004). The second Laurell Lecture was presented 
by Professor Noor Kalsheker of the Division of Clinical 
Chemistry at Queen’s Medical Centre of the University of 
Nottingham, UK.
Professor Kalsheker discussed the gene regulation 
(Kalsheker et al 2002) and genetic variation of AAT and 
the relationship with COPD. AAT is a member of the serine 
proteinase inhibitor (serpin) gene family and is now also 
referred to as SERPINA1. There are 33 different serpin gene 
sequences identiﬁ  ed in the human genome, and there are 
2 discrete clusters (chromosomes 14q 32.1 and 18q 21.3), 
each consisting of about 11 genes. These clusters contain only 
serpin genes, and their composition and structure are highly 
conserved. The way DNA is packaged provides a higher- 
order structure in terms of gene regulation. It is possible to 
explore some of the important structural elements associated 
with chromatin. Some areas of DNA are exposed by the 
manner of DNA packing, and these chromatin landmarks 
provide clues to putative regulatory elements and can be 
assessed by DNase 1 hypersensitivity sites. A region upstream 
of the AAT gene has been identiﬁ  ed that is absolutely critical 
for expression of the whole gene cluster. Within this 8-kb 
region, there is 2.3-kb DNA, the locus control region (LCR), 
which is critical for expression of the entire locus. The LCR 
controls the whole cluster, but there is also local control 
within the gene cluster.
Transcription is not a simple process and involves a 
number of proteins combining to promote gene expression 
(Figure 1). Specifically, in AAT expression, 2 main 
promoters have been found: the major hepatocyte promoter 
driving expression in the liver and, further upstream, the 
monocyte promoter that drives expression in other cell types, 
eg, lung tissue. These promoters are distinct and work via 
different mechanisms. Promoters regulate basal expression 
in the steady state, while elements in the DNA known 
as enhancers modulate expression during inﬂ  ammation. 
Several sites of local transcriptional control have been 
identiﬁ  ed upstream of the hepatocyte transcription initiation 
site, including binding sites for hepatocyte nuclear factor-1α 
(HNF-1α) and HNF4. Humoral regulation is mediated by 
cytokines, particularly interleukin-6 (IL-6) and oncostatin-
M. These cytokines work via a 3’ enhancer downstream 
of the hepatocyte promoter, and both oncostatin-M and 
IL-6 work via different response elements. Therefore, 
there are discrete binding sites providing distinct pathways 
Figure 1 Assembly of general transcription factors required for initiation 
of transcription. TFIID, a complex of transcription activating factors (TAF) 
and TATA-binding protein (TBP) binds speciﬁ  cally to a TATA sequence. The 
presence of a transcriptional inhibitor can block the transcription process 
at this step. Next, additional transcription factors IIA and IIB assemble into 
the complex. RNA polymerase II (Pol II), escorted by transcription factor 
IIF, assemble into the complex along with additional transcription factors. 
Transcription factor IIH, in the presence of ATP, phosphorylates Pol II, releases 
the polymerase and initiates transcription.  Adapted with permission from: 
Lodish H, Baltimore D, Berk A, et al. 1995. Transcriptional control of gene 
expression. In Lodish H, Baltimore D, Berk A, et al (eds).  Molecular cell biology. 
3rd ed. New York: WH Freeman and Company/Worth Publishers. Figure 11-53, 
Chapter 11, p 454.
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for regulating the acute phase response via different 
cytokines.
The promoter for other cell types is regulated by a 
different group of transcription factors known as the Sp1 
family. Here it has been suggested that RNA stability also 
inﬂ  uences expression, as some transcripts may be more 
stable than others. In the liver, there is only one transcript 
of AAT; however, in other cell types, there are a number of 
alternative transcripts. Although most AAT is manufactured 
in the liver, the tissue in the lung has a huge capacity to make 
AAT; with appropriate stimuli, expression can be increased 
approximately 100-fold (Boutten et al 1998). Indeed, it has 
been estimated that, under inﬂ  ammatory conditions, the lung 
could produce as much as one third of the amount of AAT 
produced by the liver.
Work on identifying molecular variants of AAT and how 
much genetic variation there is in the AAT gene has recently 
been undertaken. Using single nucleotide polymorphisms 
(SNPs) as markers for disease, SNP haplotypes can reveal 
information on genetic diversity and disease association. 
A large, case-controlled study of nearly 2000 subjects using 
both epidemiologic and genetic techniques to correct for 
confounders such as age and gender assigned individual data 
to haplotype on a probability basis. The study revealed that 
haplotypes of AAT, independently of PiZZ, confer an equal 
or greater risk of COPD than the PiZZ phenotype (Chappell 
et al 2004).
Epidemiology and detection
Screening can have important psychological consequences 
both on parents and the child. Experience in Sweden (Sveger 
et al 1999) has shown that the mothers of AAT-deﬁ  cient 
children suffered increased anxiety compared with controls. 
Insufﬁ  cient counselling at the time of identiﬁ  cation was 
reported by the majority of parents, which reinforces 
the importance of patient–parent education. There were, 
however, some beneﬁ  cial effects of screening. Half of the 
AAT-deﬁ  cient individuals thought that the knowledge of 
their high-risk condition had affected their lives, particularly 
their awareness of the dangers of smoking and environmental 
pollution. The majority, 88%, knew that they should avoid 
smoking to protect their lungs (Sveger et al 1997). Indeed, 
the majority of those who were identiﬁ  ed through screening 
and their parents would recommend screening for AAT 
deﬁ  ciency. 
Screening of blood donors revealed that the prevalence 
of AAT deﬁ  ciency in the US was at least 1 in 2750, which 
equates to more than 80 000 living patients in the US; 
however, only a few thousand patients are ever diagnosed 
with AAT deﬁ  ciency and only 60%–70% of these patients 
receive augmentation therapy. To improve the efﬁ  ciency 
and accuracy of AAT deficiency testing, a central 
laboratory approach has been adopted, with immunoassay, 
phenotyping, and genotyping available. A similar approach 
has also been established outside the US. However, despite 
clear recommendations from the WHO (WHO 1997) and 
an ATS–ERS working party (ATSERS 2003), physicians’ 
practices are changing minimally and slowly, and many 
physicians do not believe that they have undetected patients 
in their practices. Indeed, many physicians, as well as 
patients with COPD, remain completely unaware of the 
disease.
Recently, an approach of testing AAT concentration 
initially in serum followed by further testing for PiZZ and 
PiSZ genotypes in patients with AAT levels below 110 mg/dL 
resulted as the most cost-effective screening method of COPD 
patients (De La Roza et al 2005). This approach reduced the 
cost per sample by about 30% (€13.43 vs €19.41 [US$16.35 
vs US$23.64]) and the cost per PiZZ individual detected also 
by about 30% (€3589 vs €5189 [US$4370 vs US$6319]) 
compared with screening all samples for genotype (De La 
Roza et al 2005).
Italy is one of the European countries least affected 
by AAT deﬁ  ciency. Based on calculated allele frequency, 
approximately 3000 individuals are thought to have the PiZZ 
phenotype and a further 22 000 the PiSZ phenotype, although 
hardly any are diagnosed. Registries show a prevalence 
of rare genotypes between 1.7% and 5.7%; however, in 
Italy, this number appears to be closer to 15% in severe 
AAT deﬁ  ciency, the highest recorded thus far worldwide 
(Ferrarotti et al 2005). AAT serum levels are slightly lower 
in individuals with rare genotypes compared with PiZZ 
individuals (23 vs 26 mg/dL). Smoking also appears to be 
more common in those with rare genotypes, and COPD is 
the most common manifestation (87%), with 9% exhibiting 
both COPD and liver disease and 4% exhibiting liver disease 
alone. In conclusion, rare AAT-deﬁ  ciency variants may be 
more frequent in areas characterized by a low prevalence of 
common AAT-deﬁ  ciency variants, but these variants are just 
not detected.
Emphysema in AAT
Results of microarray techniques in human emphysematous 
tissue have been reported in the literature (Golpon et al 2004) 
(Figure 2). Severely emphysematous tissue is characterized 
by an abundance of transcripts encoding proteins involved International journal of COPD 2006:1(2) 154
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in inflammation, immune responses, and proteolysis. 
When compared with “usual” emphysematous tissue, 
AAT-deficiency-related emphysema has a similar gene 
expression proﬁ  le; however, some signiﬁ  cant differences 
exist. Interestingly, the protease caspase 9 is upregulated in 
AAT deﬁ  ciency, whereas normal levels are retained in “usual” 
emphysema. Conversely, cathepsin B is upregulated in 
“usual” emphysema and remains normal in AAT deﬁ  ciency. 
There are further differences between AAT deﬁ  ciency and 
“usual” emphysema related to protein biosynthesis, energy 
pathways, and possibly electron transfer and cellular defense 
response. These differences suggest that in AAT deﬁ  ciency, 
there is impairment in both protein and energy metabolism.
Several components affect the reaction to cigarette 
smoke. Microarray analysis in a murine model of cigarette 
smoke exposure has revealed that early lung response to 
smoke exposure comprises tissue remodeling, antioxidative 
response, and fatty acid synthesis and creates a mild 
inflammatory response. Smoke induces a limited but 
signiﬁ  cant number of hypoxia-responsive genes. All of 
these genes are associated with the hypoxia-responsive 
element (HRE) in the gene promoters and are activated 
by hypoxia-inducible factor (HIF) transcription factors. 
Therefore, the hypoxia–smoke signature could be targeted by 
anti-HIF drugs. In addition, different strains of mice have a 
different gene expression response to smoke exposure with a 
functional correlation between genotype and phenotype. This 
work suggests that some genotypes are more susceptible to 
the effects of hypoxia–smoke.
Clinical observations in siblings with the same PiZZ 
genotype and similar smoking history but different levels 
of pulmonary function have suggested that there may be 
some additional factors inﬂ  uencing the manifestation of 
emphysema. As almost all smoking AAT-deﬁ  cient patients 
will develop emphysema between the third and ﬁ  fth decades 
of life, the observation that some do not has aroused interest. 
Other genetic factors may be involved in the development 
of pulmonary emphysema in AAT-deﬁ  cient patients. This is 
supported in the literature by studies showing an increased 
prevalence of COPD in relatives of early-onset COPD 
cases without AAT deﬁ  ciency compared with relatives of 
controls. In addition, a heritability of FEV1 approximating 
35% suggests that protective or modiﬁ  er genes may play a 
role (Joost et al 2002; Silverman et al 2002; Palmer, Celedón, 
et al 2003). In order to test this hypothesis, a study using 
the AIR database is currently underway with 96 discordant 
sibling pairs. It has been calculated that this number of 
subjects should be able to detect an allele protective for the 
development of emphysema; however, it will depend on the 
penetration of the allele and the limits of detection (LOD) 
scores of the marker(s).
Liver disease in AAT
The characteristic finding in the liver associated with 
PiZZ AAT deﬁ  ciency is the accumulation of AAT within 
hepatocytes as polymers. This manifests as intracytoplasmic 
inclusion bodies formed at a basal rate in periportal 
hepatocytes. Fever further induces polymerization rate of 
type ZZ AAT. In children, the clinical manifestation of this 
disorder is neonatal hepatitis syndrome with cholestasis. 
In most cases, spontaneous clinical regression occurs 
before the age of 6 months, but in 20%–30% of cases with 
cholestasis, deterioration toward cirrhosis and liver failure 
occurs. In adults over age 45 years, a wide spectrum of liver 
disease may develop ranging between mild cirrhosis and 
hepatocellular carcinoma. Interestingly, signiﬁ  cant lung and 
liver disease in adults rarely coexist in the same individual.
AAT deﬁ  ciency is the most common metabolic–genetic 
indication for liver transplantation in children (Francavilla et 
al 2000). The majority of cases of PiZZ liver disease present 
neonatally with prolonged conjugated jaundice, pale stools, 
and dark urine. From antenatal experience, there do not 
appear to be obstetric problems or an increased incidence 
of congenital abnormalities; however, in fetuses aborted at 
Figure 2  Gene ontology (GO) categories that have a superabundance of 
differentially expressed genes in either “usual” emphysematous lung tissue (EML) 
or AAT-deﬁ  ciency-related emphysematous lung tissue (ADL) when compared 
with normal lung tissue (NML). Reprinted from Golpon HA, Coldren CD, Zamora 
MR, et al. 2004. Emphysema lung tissue gene expression proﬁ  ling. Am J Respir Cell 
Mol Biol, 31:595–600. Copyright © 2004, with permission from American Thoracic 
Society.
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17–20 weeks’ gestation with the PiZZ phenotype, 4 out of 5 
showed a build-up of AAT in the liver (Malone et al 1989). 
It has been shown that liver involvement occurs in only 17% 
of PiZZ individuals after 20 years (Sveger and Eriksson 
1995); however, it is not currently possible to predict which 
individuals will develop liver disease. Of those who develop 
neonatal hepatitis syndrome, 22% do not develop chronic 
liver disease, while 50% develop mild liver disease and the 
remaining 28% develop severe liver disease necessitating 
liver transplantation. A recent study investigating the 
relationship between phenotype and manifestation of liver 
disease revealed that there was also a signiﬁ  cant degree of 
discordance between sibling pairs regarding the severity of 
liver disease (Hinds et al 2004).
Although PiZZ liver disease is still underdiagnosed 
in adults, it is being increasingly recognized in those 
with “cryptogenic cirrhosis”, alcoholic liver disease, and 
hepatocellular carcinoma and in those receiving liver 
transplantation. Indeed, the possible relationship with co-
morbid conditions such as hepatitis B and C, autoimmune 
hepatitis, and hemochromatosis has given rise to the “second-
hit” theory, where AAT deﬁ  ciency could make the associated 
pathology more severe.
Polymerization is identiﬁ  ed as the main pathological 
event occurring in the liver. Disappointingly, very few 
papers have been published in the last few years addressing 
either liver disease or cell biology in AAT deficiency, 
especially considering that such research could shed light 
on a number of conditions. In the area of liver cell biology, 
using differential antibody binding has shown that the AAT 
polymer conformations formed by the Z, Siiyama, and Mmalton 
phenotypes are different (Janciauskiene et al 2004). Another 
study showed that by using point mutation within a surface 
hydrophobic cavity at a particular site, polymer formation 
could be reduced in the Z-type AAT molecule (Parfrey et al 
2003). Investigation of the polymerization process itself has 
revealed a kinetic lag phase during which short oligomers 
are formed prior to the formation of heterogeneous mixtures 
of longer polymers (Purkayastha et al 2005). These and 
other studies have increased overall understanding of 
protein conformation; however, this needs to be linked to 
pathogenesis and clinical outcomes.
One exciting development is in the area of protein 
processing. If small compounds that are able to act in the 
liver cell could prevent the process of polymerization, 
biochemical functional ZZ protein would be generated for 
secretion into the peripheral circulation. It has been shown 
in a tissue culture system that endoplasmic reticulum 
mannosidase I (ERManI) can contribute to the preferential 
selection of misfolded AAT monomers for proteasomal 
degradation (Hosokawa et al 2003; Wu et al 2003), which 
could provide the basis for a treatment. Six of the key genes 
involved in Z-type AAT degradation have also been identiﬁ  ed 
by a group at the University of Nevada, providing further 
potential therapeutic targets (Palmer, Kruse, et al 2003). 
Lawless et al demonstrated the “second-hit” phenomenon 
in vitro; activation of the unfolded protein response 
pathway requires an additional insult such as an increase in 
temperature, adding to understanding of the pathogenesis of 
AAT-deﬁ  ciency-related liver disease (Lawless et al 2004).
Lung disease
AAT is the major serpin in the human circulation with 
a wide spectrum of antiproteinase activity, including 
neutrophil elastase, proteinase 3, cathepsin G, and 
plasminogen activator. AAT is an acute phase protein, and 
plasma concentrations increase by more than 2 mg/mL 
during inﬂ  ammation, infections, cancer, liver disease, or 
pregnancy (Figure 3). AAT has an important role in the 
Figure 3 Structure of AAT: 3 β-sheets, 8 α-helixes. Reprinted from Janciauskiene 
S. 2001. Conformational properties of serine proteinase inhibitors (serpins) 
confer multiple pathophysiological roles. Biochim Biophys Acta, 1535:221–35. 
Copyright © 2001, with permission from Elsevier.
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resolution of inﬂ  ammation, the inhibition of the immune 
response in vivo and in vitro, and the stimulation of tissue 
repair and matrix production. AAT has been shown to block 
neutrophil activation by inhibiting adhesion to ﬁ  bronectin. 
In addition, AAT inhibits nasal interleukin-8 (IL-8) release 
in response to challenge with lipopolysaccharide (LPS), 
while in vitro AAT has been shown to inhibit the release 
of IL-8 by neutrophils (Nita et al 2005). It has also been 
suggested that AAT has antibacterial activities as well 
as anti-inﬂ  ammatory effects. AAT has also been shown 
to inhibit the LPS-induced release of TNFα, IL-1β, and 
monocyte chemotractant protein (MCP-1), while conversely 
the release of IL-10, an anti-inﬂ  ammatory cytokine, is 
increased after 18 hours. However, after only 2 hours, the 
release of both TNFa and IL-8 is signiﬁ  cantly increased 
in the presence of AAT. Therefore, it appears that AAT 
enhances the early response to LPS but acts as a suppressor 
in the long term. AAT might be extremely important, not 
only for tissue protection against protease damage, but also 
for the regulation of cellular responses to inﬂ  ammatory 
stimuli.
The major biological role of AAT is to inhibit neutrophil 
elastase, an enzyme that degrades elastin as well as basement 
membrane and other matrix components (ATSERS 2003). 
It remains to be determined how lung development and 
function is affected by AAT deficiency. Elastin drives 
septation and the formation of alveoli and at birth in 
normal-term infants; there are 150 million alveoli, which 
increases to an average of 400 million in adults. In many 
ways, the development of the lung in the antitrypsin 
deﬁ  ciency state is normal, demonstrating that at 6 years 
of age, FEV1 is close to 100% predicted in both PiZZ and 
PiSZ phenotypes. Further investigation at age 18 years also 
revealed that phenotype made no contribution to differences 
in FEV1, residual volume (RV), or total lung capacity (TLC); 
however, a significant difference in carbon monoxide 
diffusion was revealed (p = 0.01). In order to explain the 
apparently normal lung function in PiZZ individuals, factors 
that may compensate for the protease–protease inhibitor 
imbalance are sought. Increases in alpha-2 macroglobulin 
(A2M) levels at ages 8 and 18 years and secretory leukocyte 
protease inhibitor at age 26 years accompanied by decreases 
in elastase–AAT complex and neutrophil activity at ages 18 
and 26 years were found compared with normal controls. 
It is hypothesized that a corresponding increase in elastase–
A2M complex is likely and that this would downregulate 
neutrophil activity, providing a compensatory mechanism 
(Sveger et al 1998).
Conformational changes in the Z-type AAT molecule can 
lead to spontaneous polymerization, with long chains of AAT 
molecules formed. These chains can be seen under electron 
microscopy in the endoplasmic reticulum (ER) of hepatocytes 
in AAT-deficient individuals with liver disease. The Z 
mutation destabilizes a key beta-sheet in the AAT molecule, 
allowing the reactive loop of a second AAT molecule to insert 
itself and form a dimer. This highly precise, speciﬁ  c linkage 
results in reactive-loop beta-sheet polymers being formed 
of AAT (Figure 4). The mechanisms of emphysema in PiZZ 
individuals consist of 2 main factors: the activity of Z-type 
AAT is reduced in comparison with M-type AAT, and reduced 
levels of AAT reaching the lungs allow unopposed neutrophil 
elastase activity, thereby increasing proteolytic destruction. 
It is also important to note that the inﬂ  ammatory cell proﬁ  le 
is different in PiZZ emphysema compared with emphysema 
in PiMM individuals, that the AAT–elastase complex is 
chemotactic to neutrophils, and that both the AAT–elastase 
complex and AAT polymers share epitopes.
Polymerization occurs in the lungs of PiZZ individuals and 
contributes to inﬂ  ammation. It was observed that polymers 
are co-localized with neutrophils in alveolar walls; further 
investigation revealed that the presence of AAT polymers 
acts as a chemoattractant to neutrophils. Conformational 
transition of AAT from monomer to polymer converts an anti-
inﬂ  ammatory molecule into a pro-inﬂ  ammatory molecule, 
providing an additional mechanism for the development of 
lung disease.
Neutrophil elastase causes direct damage to epithelial 
cells as well as hyperplasia of mucus-producing 
cells, enhancing mucus secretion. It also has effects 
on the host defense by impairing ciliary clearance, 
cleaving complement and immunoglobulins, and 
impairing the killing of microorganisms. The problem 
in AAT deficiency is not too little antitrypsin but too 
Figure 4  Loop-sheet polymer of AAT molecules. Reproduced from Lomas DA, 
Mahadeva R. 2002. α1-Antitrypsin polymerization and the serpinopathies: pathobi-
ology and prospects for therapy. J Clin Invest, 110:1585–90. Copyright © 2002, with 
permission from American Society for Clinical Investigation.International Journal of COPD 2006:1(2) 157
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much in the wrong place. The accumulation of misfolded 
Z-type AAT in the endoplasmic reticulum (ER) causes 
ER stress. Cells respond to ER stress by inducing the 
expression of novel genes whose products are designed 
to restore proper ER function but can also be pro-
inflammatory. The ER stress pathways, including the 
unfolded protein response, ER overload, and apoptosis, 
appear to increase IL-8 production and neutrophil 
chemoattraction. AAT-deficiency-related lung disease 
clearly is not due purely to a lack of antiprotease on the 
respiratory epithelial surface.
It can be seen that in sputum, the activity of elastase is 
greater in PiZZ patients, as would be expected. However, 
similar experiments also reveal higher levels of tumor 
necrosis factor-alpha (TNFα) and leukotriene B4 (LTB4) in 
AAT-deﬁ  cient patients, while there is no signiﬁ  cant increase 
in IL-1β or IL-8 levels compared with physiologically 
matched controls. Sputum samples from PiZZ individuals 
also show greater chemotactic activity compared with PiMM 
samples. Investigations have shown that LTB4 provides a 
signiﬁ  cant proportion of the chemotactic activity associated 
with AAT deﬁ  ciency. This suggests that elastase may be 
driving macrophages to produce LTB4 as a mechanism for 
neutrophil recruitment.
Antimicrobial peptides (AMPs) are produced by 
epithelial cells, neutrophils, and macrophages and, in addition 
to exerting an in vitro antimicrobial effect, they have also 
been shown to stimulate the epithelium, angiogenesis, and 
both the innate and adaptive immune systems. It has been 
shown that levels of the AMPs, also known as α-defensins, 
are higher in those with AAT-deﬁ  cient lung disease (Spencer 
et al 2004). Exact functions of AMPs are not yet clear, but 
they could be acting as inﬂ  ammatory mediators and further 
research was needed.
There is considerable interest in discovering an easily 
measurable biomarker for pulmonary emphysema in 
humans, and work on biomarkers of elastin degradation 
in body ﬂ  uids is undergoing a revival. The problem with 
elastin peptides is that they are hard to evaluate and 
characterize and thus special attention has been focused 
on desmosines. This is an unusual, tetrafunctional, 
pyridinium ring-containing amino acid involved in elastin 
cross-linking that is unique to mature, cross-linked 
elastin. A number of studies show a relationship between 
excretion of desmosines in the urine and COPD (Stone et 
al 1995; Gottlieb et al 1996). However, plasma is thought 
to be a better ﬂ  uid for the determination of desmosine 
concentration, and good correlation between urine and 
plasma concentrations has been demonstrated (Annovazzi 
et al 2004). It is reported that in 12 patients with emphysema 
associated with PiZZ AAT deﬁ  ciency assessed over 7 weeks, 
there was a good correlation between lung diffusion capacity 
(% predicted KCO) and plasma desmosine (p < 0.01) and 
urine desmosine (p < 0.05) levels (Stolk et al 2005). Further 
investigation of the usefulness of desmosine as a biomarker 
for emphysema is ongoing.
Imaging
COPD has been deﬁ  ned as airﬂ  ow obstruction that is not fully 
reversible (Pauwels et al 2001). FEV1 is a nonspeciﬁ  c measure 
that fails to identify the relative contribution of the component 
parts of the COPD. This has led to the development of 
computed tomography (CT) lung densitometry because it is 
an extremely good tool for identifying changes in the lung, 
which can provide objective quantiﬁ  cation of parenchmyal 
changes. Emphysema involves a reduction in lung tissue 
density, and this is often shown by an increase in the voxel 
index, representing a shift in the voxel distribution histogram 
to more low-density voxels. CT densitometry has been 
validated in a number of studies and, importantly, the relation 
of progression in CT to deterioration in health status has been 
assessed in a longitudinal study (Stolk et al 2003). It has, 
however, been noted that although FEV1 and KCO correlate 
well in a large patient cohort, some patients are discordant 
for these measures. It has therefore been hypothesized that 
this discordance represents differences in the distribution 
of emphysema within the lung. A recent study showed 
that the emphysema distribution in PiZZ patients is more 
heterogeneous than conventional basal predominance 
descriptions indicate (Parr et al 2004a). It was also found 
that on average, those with basal emphysema have lower 
FEV1 scores, while those with apical predominant disease 
have lower KCO scores. Using a single physiologic index to 
assess emphysema may introduce systematic bias depending 
on where the emphysema is located.
Investigation of the validation of CT data over time 
revealed a number of potential factors influencing 
these types of measurements, including variability 
between scanners and the importance of calibration 
(Parr et al 2004). Standardized protocols are needed to 
improve agreement between different centers. Further 
validation of CT as a measure of disease progression in 
34 PiZZ individuals characterized annually over 3 years 
conﬁ  rmed a correlation between annual change in CT 
densitometry and FEV1. Recent advances in magnetic 
resonance imaging (MRI) of the lung using hyperpolarized International journal of COPD 2006:1(2) 158
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helium-3 (3He) have been reported. Conventional proton 
MRI in the lung could be problematic due to the large 
number of air–tissue interfaces giving rise to susceptibility 
gradients and the lower proton density of the lungs leading 
to a weak MRI signal. However, hyperpolarized 3He can 
also produce a magnetic resonance signal, and this nontoxic 
gas can be inhaled for lung imaging. Images taken from 
lungs of AAT-deﬁ  cient, “usual” emphysema, and healthy 
control subjects showed that distribution of the gas was 
not as homogeneous in the lungs of the AAT-deﬁ  cient 
patient as in the lungs of a healthy control. The lower lobe 
predominance of emphysema in the AAT-deﬁ  cient patient 
was also noticeable compared with a smoke-induced 
COPD patient where defects appeared more evenly spread 
throughout the lung. Good correlation between percent 
ventilation defect as measured from 3He MRI and lung 
function tests has been shown. In such studies, the apparent 
diffusion coefﬁ  cient (ADC) varies according to the size of 
the alveolus and expresses the mean area–velocity of the 
nuclei in a voxel. Calculating the ADC can provide a map 
of diffusion gradients throughout the lung. In a longitudinal 
study comparing ADC maps of the lung obtained via 3He 
MRI in 8 PiZZ and 8 PiMM patients with emphysema 
and 8 healthy volunteers, it was found that there was a 
signiﬁ  cant difference in mean ADC between PiZZ patients 
compared with PiMM patients. However, there was only 
a minimal, nonsigniﬁ  cant difference in carbon monoxide 
diffusing capacity (DLCO) between the 2 groups. This 
suggests that measurement of ADC with hyperpolarized 
3He diffusion MRI is a sensitive method for the assessment 
of emphysema and may make the detection and monitoring 
of early emphysema and small changes possible.
Treatment
A meta-analysis of clinical trials investigating the efﬁ  cacy 
of augmentation therapy in AAT deficiency pulmonary 
disease was presented during the meeting (Figure 5). Five 
studies were included in the meta-analysis (Seersholm et al 
1997; AATDRSG 1998; Dirksen et al 1999; Wencker et al 
2001; Chapman et al 2005) with UK registry data used for a 
comparison with untreated patients. The results suggested a 
reduced rate of FEV1 decline in AAT-deﬁ  cient individuals, 
with baseline FEV1 being an important predictor of beneﬁ  t. 
There were limitations in this analysis, including the lack of 
randomized controlled trials, variable dosing schedules of the 
augmentation therapy, and an increasing belief that FEV1 is 
not necessarily the best endpoint to measure.
It is known that an AAT infusion of 60 mg/kg every 7 days 
can maintain serum total AAT concentrations higher than 
0.5 g/L during the interval between doses (ATSERS 2003) 
The inconvenience of life-long weekly infusions of AAT 
has led to the suggestion that extended dosage regimens 
(every 14, 21, or 28 days) may be preferable. Population 
pharmacokinetic studies could assist in determining the 
biochemical efﬁ  cacy of prolonged regimens. Using a Monte-
Carlo simulation, a number of doses and frequencies were 
tested to see if total serum concentrations of AAT higher than 
0.5 g/L could be maintained throughout the dosing interval. 
Preliminary results show that AAT dosage regimens every 
2 or 3 weeks may be adequate, but to extend the interval 
between doses to 21 days requires a large increase in the dose 
of AAT administered in order to maintain total serum AAT 
concentrations above the recommended target.
AAT augmentation therapy appears to be associated with 
a marked reduction in the frequency and severity of lung 
infections (Lieberman 2000) as well as a reduction in the 
loss of lung tissue as measured by CT scanning (Dirksen 
et al 1999) compared with untreated patients. As a result 
of these observations, the EXACTLIE (Exacerbations and 
CT Scanning in Laurell’s Syndrome as Investigational 
Endpoints) trial has been designed. This is a multicenter, 
randomized, placebo-controlled, double-blind, exploratory 
trial with parallel groups that will investigate the progression 
of disease in 80 patients with AAT deficiency treated 
with AAT or placebo for 2 years. The efﬁ  cacy of weekly 
intravenous AAT (Prolastin®; Talecris, Clayton, NC, USA) 
infusions in AAT-deﬁ  cient patients with regard to lung 
density and exacerbations compared with placebo will also 
be assessed. Since October 2003, 76 patients have been 
enrolled in the study. To date, few serious adverse events 
have occurred and none were thought to be related to the 
study drug.
Figure 5 Rate of FEV1 decline: augmentation vs control (Seersholm et al 1997; 
AATDRSG 1998; Dirksen et al 1999; Wencker et al 2001; Chapman et al 2005).
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Current developments in alpha1-antitrypsin deﬁ  ciency
Gene therapy is still considered to be of potential use. 
Currently the approach of an intramuscular injection of 
the AAT gene using a recombinant adeno-associated virus 
(rAAV) vector, AAV-2, is being studied. The long-term, 
high-level expression of AAT from muscle in mice has 
been previously demonstrated (Song et al 1998). A phase I, 
single- site, open-label, single-dose safety study is currently 
underway involving 4 cohorts of 3 subjects with dose 
escalation between cohorts. Preliminary ﬁ  ndings indicate 
that the treatment is safe with no serious vector-related 
adverse effects and no evidence of cell-mediated immunity; 
however, signiﬁ  cant changes in serum levels of muscle-
derived AAT have yet to be detected. Future directions for 
research may include the use of different vectors, such as 
AAV-1, which may increase the level of AAT expression. 
Another AAV vector, AAV-8, shows promise in treating 
liver disease because it shows great potential in transducing 
hepatocytes, not only for secreting AAT, but also for 
transducing a greater number of hepatocytes compared with 
other AAV vectors.
Conclusion
Currently available intravenous replacement therapy is 
aiming only at the prevention of lung disease progression. It 
has no effect on liver disease and does not induce repair of 
lung injury. While few new treatments for AAT deﬁ  ciency 
are on the near horizon (such as inhaled AAT or synthetic 
oral elastase inhibitors), understanding the biochemistry 
of PiZZ AAT and its downstream effects may lead to new 
concepts of treatment. For example, trying to prevent the 
polymerization of PiZZ AAT by inserting small compounds 
into a hydrophobic cavity bounded by the D and E helices 
in AAT would allow release of functional active PiZZ 
AAT to the circulation and prevent the development or 
progression of cirrhosis. Likewise, at the level of cellular 
systems, small compounds that release type ZZ AAT from 
hepatocytes are currently being explored as chaperone-based 
therapy. Modiﬁ  er genes that clarify the difference in disease 
phenotype of sib pairs with equal smoking history and equal 
genotype could provide insight into new therapeutic concepts 
and the clinical epidemiology of individuals who will or will 
not develop lung and/or liver disease. Finally, the aim to 
switch on repair mechanisms in the lung is currently being 
studied in a proof-of-concept study in the PiZZ population 
with emphysema.
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